Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 3, 2009, Pages 593-599

  Santos, André F ^a   Abecasis, Ana B ^b,c   Vandamme, Anne Mieke ^c   Camacho, Ricardo J ^b,d   Soares, Marcelo A ^a,e  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b HOSPITAL EGAS MONIZ   (Portugal)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^d INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

^e INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

Drug susceptibility; I54V; Indinavir; L90M; Nelfinavir; Phenotyping

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; SAQUINAVIR;

ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EXPOSURE; GENE MUTATION; GENETIC ALGORITHM; GENETIC SELECTION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHENOTYPE;

AMINO ACID SUBSTITUTION; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; MUTATION, MISSENSE; NELFINAVIR; PORTUGAL; SAQUINAVIR; SELECTION (GENETICS);

EID: 60649120957     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn526     Document Type: Article

References (24)

1. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med 2004; 350 1023-35.
2. Johnson VA, Brun-Vezinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med 2008; 16: 62-8.
3. Robertson DL, Anderson JP, Bradac JA et al. HIV-1 nomenclature proposal. Science 2000; 288: 55-6.
4. Hemelaar J, Gouws E, Ghys PD et al. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006; 20: W13-23.
5. UNAIDS. 2008 Report on the Global AIDS Epidemic. http://data.unaids.org/pub/GlobalReport/2008/ JC1511_GR08_ExecutiveSummary_en.pdf (2 December 2008, date last accessed).
6. Baldanti F, Paolucci S, Ravasi G et al. Changes in circulation of B and non-B HIV strains: Spotlight on a reference centre for infectious diseases in Northern Italy. J Med Virol 2008; 80: 947-52.
7. Paraskevis D, Magiorkinis E, Magiorkinis G et al. Increasing prevalence of HIV-1 subtype A in Greece: Estimating epidemic history and origin. J Infect Dis 2007; 196: 1167-76.
8. Falkensammer B, Doerler M, Kessler HH et al. Subtype and genotypic resistance analysis of HIV-1 infected patients in Austria. Wien Klin Wochenschr 2007; 119: 181-5.
9. Palma AC, Araújo F, Duque V et al. Molecular epidemiology and prevalence of drug resistance-associated mutations in newly diagnosed HIV-1 patients in Portugal. Infect Genet Evol 2007; 7: 391-8.
10. Abecasis AB, Deforche K, Bacheler LT et al. Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02_AG. Antivir Ther 2006; 11: 581-9.
11. Gonzalez LM, Brindeiro RM, Tarin M et al. In vitro hypersusceptibility of human immunodeficiency virus type 1 subtype C protease to lopinavir. Antimicrob Agents Chemother 2003; 47: 2817-22.
12. Gonzalez LM, Santos AF, Abecasis AB et al. Impact of HIV-1 protease mutations A71V/T and T74S on M89I/V-mediated protease inhibitor resistance in subtype G isolates. J Antimicrob Chemother 2008; 61: 1201-4.
13. Kantor R, Katzenstein DA, Efron B et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. PLoS Med 2005; 2 e112.
14. Hertogs K, de Bethune MP, Miller V et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998; 42: 269-76.
15. Verlinden Y, Vermeiren H, Lecocq P et al. Assessment of the Antivirogram® performance over time including a revised definition of biological test cut-off values. Antivir Ther 2005; 10: S51.
16. Rhee SY, Gonzales MJ, Kantor R et al. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 2003; 31: 298-303.
17. Abecasis AB, Deforche K, Snoeck J et al. Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G. AIDS 2005; 19: 1799-806.
18. Pol in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response. Virology 2008; 378: 272-81.
19. Soares EA, Santos AF, Sousa TM et al. Differential drug resistance acquisition in HIV-1 of subtypes B and C. PLoS One 2007; 2: e730.
20. Grossman Z, Paxinos EE, Averbuch D et al. Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir. Antimicrob Agents Chemother 2004; 48: 2159-65.
21. Camacho R, Deforche K, Valadas ME et al. Nelfinavir resistance in HIV-1 subtype B and G infected patients: Evidence for different pathways and novel mutations associated with failure of nelfinavir based regimens. Antivir Ther 2004; 9: U83.
22. van de Vijver DA, Wensing AM, Angarano G et al. The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defic Syndr 2006; 41: 352-60.
23. Camacho R, Godinho AR, Gomes P et al. Different substitutions under drug pressure at protease codon 82 in HIV-1 subtype G compared with subtype B infected individuals including a novel I82M resistance mutation. Antivir Ther 2005; 10: S151.
24. Brenner B, Turner D, Oliveira M et al. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 2003; 17 F1-5.